Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Feb 25, 2021
Beam adds to drug delivery stable with USD 120 Million GuideTx buy Beam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicines to more tissues in the body, widening the potential to approach more diseases. Beam announced that it paid USD 120 million upfront to acq...
Read More...
Feb 04, 2021
Plaque psoriasis drug outshines the competition in phase III trial Bristol Myers Squibb’s psoriasis drug, the TYK2 inhibitor outshone placebo and Amgen’s Otezla in a second phase 3 study, setting discussions with regulators. The study, known as POETYK PSO-2, trialled the drug, deucravacitinib, against placebo...
Read More...
Jan 28, 2021
Nirogy Therapeutics rises with USD 16.5 Million to target metabolite transporters Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small molecules for targeting cellular transporters, announced the closing of a USD 16.5 million Series A financing. Nirogy plans to use the...
Read More...
Jan 07, 2021
Ikena secures USD 120 Million to advance a growing pipeline of cancer drugs Ikena Oncology has bagged USD 120 million to develop its expanding pipeline of cancer drugs. The Series B round begins as Ikena prepares to add a TEAD inhibitor to its roster of clinical programs and pushes a first-in-class KRAS asset th...
Read More...
Dec 31, 2020
Improving cancer immunotherapy by recovering a warning system Cancer cells, most of the time, develop tactics to elude the immune system. A research team that is led by scientists at Memorial Sloan Kettering Cancer Center has recognized one such mechanism, and it believes aiming it with drugs could potentially e...
Read More...
Dec 24, 2020
NIH awards USD 107 Million for radical COVID-19 testing tech The National Institutes of Health (NIH) awarded over USD 107 million for radical approaches to testing for COVID-19 and tracing the spread of the disease, including cutting-edge technologies, which could make daily coronavirus testing less interf...
Read More...
Dec 10, 2020
AstraZeneca’s COVID-19 vaccine data suggest single-dose efficacy The full data from late-phase trials of AstraZeneca’s COVID-19 vaccine have pointed to the potential for AZD1222 to work after a single dose and limit asymptomatic cases; however, missed main questions regarding the efficacy of the candidate. Th...
Read More...
Nov 12, 2020
FDA authorizes first diagnostic test for COVID-19 antibodies that obstruct the virus from entering cells The FDA has authorized the first COVID-19 diagnostic test, which identifies whether a person has the specific antibodies known to hinder the coronavirus from entering and infecting human cells. These neutr...
Read More...
Oct 22, 2020
GSK eyes robust immune response from RSV vaccine Cold viruses mostly do not get much attention in terms of R&D. They usually make humans feel miserable for a few days, and later than clear up. However, some cold viruses can hit vulnerable people much harder, which leads to pneumonia and hospitalizations. Th...
Read More...
Oct 08, 2020
Designing a universal flu vaccine by focusing on the immune system A universal flu vaccine that can foster protection to people against any influenza strain is considered a goal in flu research as it could spare scientists from the often erroneous process of predicting the circulating strains each year and...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper